Allogene Therapeutics, Inc. 8K

Allogene Therapeutics announced Q2 2026 results, highlighted key clinical progress including RMAT and Fast Track designations for cema-cel in LBCL, and projected its cash runway into 2029.

Allogene Therapeutics, Inc. reported its second quarter 2026 financial results and provided a business update highlighting progress in its key allogeneic CAR T programs, including positive interim futility analysis data from the pivotal Phase 2 ALPHA3 trial of cemacabtagene ansegedleucel (cema-cel) in first-line large B-cell lymphoma that supported the FDA granting RMAT and Fast Track designations, continued rapid enrollment in the Phase 1 RESOLUTION trial of ALLO-329 in autoimmune diseases with a data update expected in Q4 2026, and a strengthened balance sheet with $423.6 million in cash, cash equivalents and investments and projected cash runway into 2029 despite a Q2 2026 net loss of $42.7 million.

Filing Facts

CIK

1737287

Ticker

ALLO

Form

8K

Source Type

fda

Accession

0001628280-26-056198

Alert Tier

6